Superficial Keratitis, as genome-wide studies have reported it: 5 positions from 1 study, the largest recording 2,528 cases and 623,139 controls (African American or Afro-Caribbean ancestry, European ancestry, Hispanic or Latin American ancestry). Every figure comes from the studies themselves, gathered by code from the GWAS Catalog and updated as the records grow.
Superficial Keratitis — filed in the GWAS Catalog as "Superficial keratitis (PheCode 370.2)" — is a condition this catalogue follows as its positions arrive. This page is assembled by MyGeneLog's own code from the catalogue's records and the studies' own listings: 5 positions from 1 study, and no sentence written by hand. It is rebuilt as new positions are reported, so what it says is what the records say today.
Verma A et al. 2024, in Science — Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. Studied in 2,528 cases and 623,139 controls (African American or Afro-Caribbean ancestry, European ancestry, Hispanic or Latin American ancestry). The 5 positions on this page from it: rs183640372 (STK11), rs184421129 (ADCY2), rs745494800 (IL17RE), rs189464266 (KLF17), rs922468689 (NT5C1B-RDH14). PMID:39024449.
The 5 positions sit in or beside 5 genes: STK11, ADCY2, IL17RE, KLF17, NT5C1B-RDH14. These are locations, as the catalogue records them; whether any of these genes is how a position acts is a question the records leave open.
Of all these, rs183640372 in STK11 carries the strongest signal: P = 3 × 10-13, in Verma A et al. 2024.
It is a record of what genome-wide studies have reported about Superficial Keratitis, kept current by code. It is not a description of the condition, an estimate of how common it is, or guidance of any kind — a page that took those from association records would be inventing them. Each variant page linked here carries that study's own record for the position in fixed sentences, and ClinVar's record where one exists.
Nothing on this page diagnoses Superficial Keratitis. The 5 variants here are research findings; no guideline uses them to predict, screen for or diagnose the condition — that is a clinician's work.
Its sources are association records, and association records carry no clinical guidance, so neither does this page. What a genome-wide study reports is a difference between groups of people, not a finding about any one person. Symptoms, tests and treatment are questions for a clinician.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Superficial Keratitis comes down to these specific, well-studied positions — not a diagnosis.
Databases, guidelines and references
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Superficial Keratitis. MyGeneLog™. https://www.mygenelog.com/conditions/superficial-keratitis
Superficial Keratitis is the condition the GWAS Catalog files under "Superficial keratitis (PheCode 370.2)". This page does not define it in its own words; it lists what genome-wide studies have reported: 5 positions from 1 study, with each study's sample and citation.
Genes play a part: 5 positions have been linked to it, the largest study recording 2,528 cases and 623,139 controls (African American or Afro-Caribbean ancestry, European ancestry, Hispanic or Latin American ancestry). But each is a common variant of small effect, and a link found across a population does not cause the condition in any one person.
The catalogue maps the positions to 5 genes: STK11, ADCY2, IL17RE, KLF17, NT5C1B-RDH14. These are where the positions sit, not proof of how they act.
No. Each variant shifts the odds only slightly, and only on average across many people. No guideline predicts Superficial Keratitis from a genotype; a clinician diagnoses it.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.